LONDON (Reuters) - British liquid biopsy company Angle said its Parsortix blood test had beaten current methods in identifying ovarian cancer, a breakthough that could help women receive the best possible outcome from surgery.
Patients treated with intensity-modulated radiation therapy (IMRT) for cervical or endometrial cancer have fewer adverse events and experience better quality of life than those treated with conventional radiation therapy (RT), according to research presented at the 2016 American Society for Radiation Oncology (ASTRO) Annual Meeting (September 25-28; Boston, MA).
Prolonging platinum-free interval (PFI) by introducing non-platinum-based chemotherapy may actually worsen efficacy outcomes in patients with recurrent ovarian cancer, according to clinical trial results presented at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago, IL (June 3-7).
Women with advanced ovarian cancer who express a certain tumor antigen will likely experience a shorter progression-free survival (PFS) and overall survival (OS) than those without the antigen, according to research published in Gynecologic Oncology (June 2017;145:420-425).
The treatment landscape in the coming decade for ovarian cancers will likely feature poly ADP ribose polymerase (PARP) inhibitors in combination with other treatments, according to reports from a recent conference.
Women with BRCA-mutated relapsed serous ovarian cancer who received maintenance therapy after platinum-based chemotherapy prolonged their progression-free survival (PFS) by almost 7 months, according to results of a study presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).
Patients receiving treatment for ovarian cancer experienced a significant out-of-pocket financial burden, due largely to cost disparities across treatment types and a lack of definitive treatment options, according to research presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).